ViGeneron is based on our passion to deliver gene therapy innovations and advances to people in need. Our proprietary science solves major limitations in current gene therapy approaches.
At ViGeneron we are dedicated to developing innovative gene therapies to treat ophthalmic diseases with high unmet medical need, as well as partnering with leading biopharmaceutical players in various disease areas such as Ophthalmology, CNS, cardiac, etc.
The company’s pipeline is built on unique and proprietary adeno-associated virus (AAV) technology platforms. The first, vgAAV gene therapy vector platform, allows superior transduction efficiency and intravitreal, less invasive treatment administration. The second, REVeRT vector platform, targets diseases caused by mutations in genes larger than 5kb.
At ViGeneron we are dedicated to developing innovative gene therapies to treat ophthalmic diseases with high unmet medical need, as well as partnering with leading biopharmaceutical players in various disease areas such as Ophthalmology, CNS, cardiac, etc.
The company’s pipeline is built on unique and proprietary adeno-associated virus (AAV) technology platforms. The first, vgAAV gene therapy vector platform, allows superior transduction efficiency and intravitreal, less invasive treatment administration. The second, REVeRT vector platform, targets diseases caused by mutations in genes larger than 5kb.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Germany
Year Founded:
2017
Main Therapeutic Focus:
Gene/Cell Therapy
Lead Product in Development:
VG901
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
